– Submission of a file to the Chinese authorities (“NMPA”) to obtain renewed approval of the PediGuard range currently available in China, as well as its extension to the PediGuard Curve and XS models
PARIS, BOULDER (Colorado-United States), March 5, 2024 – 6:00 p.m. CET – SpineGuard (FR0011464452 – ALSGD, PEA-PME eligible), innovative company that deploys its digital real-time surgical guidance technology (DSG®) by measurement local electrical conductivity of tissues in real time to secure and simplify the placement of bone implants, today announces that it has made progress in its Chinese regulatory plan by submitting to the Chinese authorities (“NMPA”) a file intended to obtain the renewed approval of the PediGuard range currently available in China, as well as its extension to the PediGuard Curve and XS models whose technical tests for regulatory purposes have just been launched in China in a specialized laboratory.
To receive all of SpineGuard’s financial information in real time, request it by email to [email protected].